Recently, it has been reported that inhibition of the NF-κB-inducing kinase (NIK) of the non-canonical NF-κB pathway in murine and human monocyte-derived DCs can decrease IL-12p40 production in vitro, and global inhibition of NIK in BWF1 can ameliorate SLE manifestations [53]. The gene discussed is NFKB1; the disease is systemic lupus erythematosus.